Teva, Impax, Allergan deal

Teva will sell a portfolio of generic products to Impax for $586 million. The deal includes 15 marketed generics, three approved products that

Read the full 238 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE